📰 Repligen Daily News
Page 2 - Repligen Daily News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Repligen Daily. Real-time updates on events, politics, business and more.
March 9, 2024
Dana Investment Advisors Inc. lowered its stake in Repligen Co. (NASDAQ:RGEN – Free Report) by 36.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,437 shares of the biotechnology company’s stock after selling 2,546 shares during the period. Dana Investment Advisors […]
March 9, 2024
Dana Investment Advisors Inc. lessened its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 36.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,437 shares of the biotechnology company’s stock after selling 2,546 shares during […]
March 9, 2024
WealthPlan Investment Management LLC purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,320 shares of the biotechnology company’s stock, valued at approximately $210,000. A number of other hedge […]
February 28, 2024
Repligen Co. (NASDAQ:RGEN – Free Report) – Stock analysts at William Blair cut their Q1 2024 earnings per share (EPS) estimates for shares of Repligen in a research report issued to clients and investors on Thursday, February 22nd. William Blair analyst M. Larew now forecasts that the biotechnology company will earn $0.30 per share for […]
February 27, 2024
Primecap Management Co. CA boosted its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 6.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,629 shares of the biotechnology company’s stock after purchasing an additional 3,250 shares […]
February 23, 2024
Repligen Co. (NASDAQ:RGEN – Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $199.73, but opened at $187.80. Repligen shares last traded at $198.30, with a volume of 185,706 shares changing hands. Wall Street Analysts Forecast Growth A number of brokerages recently weighed in on RGEN. KeyCorp […]
February 23, 2024
DekaBank Deutsche Girozentrale grew its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 1.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,457 shares of the biotechnology company’s stock after buying an additional 159 shares […]
February 22, 2024
Repligen (NASDAQ:RGEN – Get Free Report) released its earnings results on Wednesday. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33, Briefing.com reports. The business had revenue of $155.74 million for the quarter, compared to analyst estimates of $155.38 million. Repligen had a return on equity […]
February 22, 2024
Repligen (NASDAQ:RGEN – Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33, Briefing.com reports. The company had revenue of $155.74 million during the quarter, compared to analysts’ expectations of $155.38 million. Repligen had a return on equity […]
February 21, 2024
Repligen (NASDAQ:RGEN – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $1.42-1.49 for the period, compared to the consensus estimate of $1.77. The company issued revenue guidance of $620-650 million, compared to the consensus revenue estimate of $660.67 million. Repligen also […]